Oncovita is pioneering the development of innovative cancer therapies through its proprietary Measovir™ platform, which utilizes a modified measles virus to create oncolytic vaccines. This technology leverages the natural oncolytic properties of the measles virus, which preferentially targets cancer cells due to the overexpression of the CD46 receptor on their surface. The MVdeltaC vaccine, a key product derived from this platform, has shown promising preclinical results, demonstrating a strong capacity to induce immunogenic cell death in various cancer types, including mesothelioma and bladder cancer. The platform's design allows for the generation of recombinant viruses that can express additional genetic material, enhancing their therapeutic potential.

The Measovir™ platform not only aims to destroy cancer cells but also to activate the immune system, promoting a long-lasting anti-tumor response. By inducing the release of danger signals and tumor-associated antigens, the treatment enhances the activation of dendritic cells and T cells, which are crucial for effective immune responses against tumors. Oncovita's approach represents a significant advancement in cancer immunotherapy, with the potential to address unmet medical needs in oncology by providing safe and effective treatment options that harness the body's own immune defenses.

France

Oncovita is a preclinical stage biotech company pioneering the development of oncolytic viruses to address unmet medical need. Led by a world-class management, Oncovita is focused on developing innovative medications and vaccines, particularly anti-cancer therapies, to save lives.

Oncovita

Company Details